Elutia (ELUT) Net Income towards Common Stockholders (2019 - 2026)
Elutia (ELUT) reported Net Income towards Common Stockholders of $425000.0 for Q1 2026, up 110.81% on a YoY basis from $201607.2 in Q1 2025, and down 97.57% sequentially from $17.5 million in Q4 2025.
Elutia (ELUT) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends
Elutia (ELUT) has 8 years of Net Income towards Common Stockholders data on file, last reported at $425000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 110.81% year-over-year to $425000.0; the trailing twelve-month figure through Mar 2026 stood at $4.4 million (down 68.01% YoY), and the FY2025 full-year result was $53380.0, up 198.95% from the prior year.
- Net Income towards Common Stockholders retreated to $425000.0 in Q1 2026, from $17.5 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $44.8 million in Q4 2024 to a low of -$28.2 million in Q2 2024.
- A 5-year average of -$4.4 million and a median of -$8.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders jumped 447.36% in 2024 and tumbled 462.51% in 2025, its largest moves.
- Tracing ELUT's Net Income towards Common Stockholders over 5 years: stood at -$5.4 million in 2022, then slumped by 137.26% to -$12.9 million in 2023, then jumped by 447.36% to $44.8 million in 2024, then tumbled by 61.05% to $17.5 million in 2025, then sank by 97.57% to $425000.0 in 2026.
- Business Quant data shows ELUT's Net Income towards Common Stockholders at $425000.0 in Q1 2026, $17.5 million in Q4 2025, and -$3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Elutia | 40.03 Mn | 11.54 Mn | 1.80 Mn | 425,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 425,000.00 |
| Dec 31, 2025 | 17.46 Mn |
| Sep 30, 2025 | -3.87 Mn |
| Jun 30, 2025 | -9.61 Mn |
| Mar 31, 2025 | -3.93 Mn |
| Dec 31, 2024 | 44.83 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | -28.18 Mn |
| Mar 31, 2024 | -17.99 Mn |
| Dec 31, 2023 | -12.91 Mn |
| Sep 30, 2023 | -9.75 Mn |
| Jun 30, 2023 | -7.73 Mn |
| Mar 31, 2023 | -9.78 Mn |
| Dec 31, 2022 | -5.44 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Jun 30, 2022 | -9.40 Mn |
| Mar 31, 2022 | -8.15 Mn |
| Dec 31, 2021 | -9.06 Mn |
| Sep 30, 2021 | -8.32 Mn |
| Jun 30, 2021 | -2.39 Mn |